SHR0302 + SHR0302 placebo

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis

Trial Timeline

Oct 14, 2020 → May 12, 2023

NCT ID

NCT04481139

About SHR0302 + SHR0302 placebo

SHR0302 + SHR0302 placebo is a phase 2/3 stage product being developed by Jiangsu Hengrui Medicine for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04481139. Target conditions include Ankylosing Spondylitis.

What happened to similar drugs?

20 of 20 similar drugs in Ankylosing Spondylitis were approved

Approved (20) Terminated (4) Active (0)

✅Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved

✅GolimumabJohnson & JohnsonApproved

✅AdalimumabAbbVieApproved

✅InfliximabMerckApproved

✅GolimumabMerckApproved

✅RemicadeMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05324631	Phase 3	UNKNOWN	Aug 16, 2022	Dec 11, 2024	Non-radiographic Axial Spondyloarthritis
NCT04481139	Phase 2/3	Completed	Oct 14, 2020	May 12, 2023	Ankylosing Spondylitis

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors

Product	Company	Stage	Hype Score
Infliximab	Celltrion	Phase 1	29
Infliximab	Celltrion	Phase 1	29
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
adalimumab	Eisai	Phase 3	40
Ixekizumab + Placebo + Adalimumab	Eli Lilly	Phase 3	32
Tramadol /acetaminophen + Diclofenac	Johnson & Johnson	Approved	35
Golimumab + Placebo	Johnson & Johnson	Phase 3	40
Golimumab	Johnson & Johnson	Approved	43
placebo for risankizumab + risankizumab	AbbVie	Phase 2	35
Adalimumab	AbbVie	Approved	39
Upadacitinib + Placebo	AbbVie	Phase 2	35
Adalimumab	AbbVie	Pre-clinical	26
infliximab + Placebo	Merck	Phase 3	40
Infliximab	Merck	Approved	35
Infliximab + Placebo + Naproxen	Merck	Phase 3	40
Infliximab	Merck	Pre-clinical	26
Golimumab	Merck	Approved	43
Remicade	Merck	Approved	43
Remicade	Merck	Approved	43
Infliximab	Merck	Approved	43